TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06185673: A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Sponsor: Benitec Biopharma, Inc. · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 30 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,008,000

Rescue Site Savings

+$9,236,525

Unlock Full NCT06185673 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06185673 Rescue Dossier →